"Company Markets Reputed Anti-AIDS Cream for Health-Care Workers"

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

"Company Markets Reputed Anti-AIDS Cream for Health-Care Workers"

United Press International (12/16/92)

Abstract: Pompano Beach, Fla.--A hand-cream that allegedly kills HIV infection is being marketed despite Food and Drug Administration concerns. Knight Industries Inc. has begun marketing what it calls "liquid glove" intended for health-care workers. But the FDA said Wednesday that it started an investigation of "Viro Glove" cream, which regulators insist needs government approval before being marketed. Monica Revelle, FDA spokeswoman, said, "At this point, it could be premature to say what actions we might take. (But) we consider (the product) a drug, and right now, it is unapproved." However, Knight Industries maintains that Viro Glove is a "device," not a medicine, therefore no FDA-approval is needed. Knight Industries spokeswoman Colleen McMurray said Knight had submitted all required reports on the cream's safety and efficacy to the FDA. In addition, she said that the product passed a 90-day waiting period without any government challenge. McMurray asserted that Viro Glove provides health-care workers with protection from HIV infection for four to six hours. It also helps protect against gonorrhea and influenza. She said, "Our target market is at-risk health professionals: emergency-medical technicians, police, school nurses--anybody who comes into contact with blood or blood pathogens due to their occupations." McMurray also said that Viro Glove contains the spermicide Nonoxynol-9 and will sell for $19.95 per 8-ounce bottle.

921216
AD922441

Copyright © 1992 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.